Zealand Pharma and Roche reported Phase 2 results for petrelintide, an amylin-receptor–targeting peptide, showing tolerability comparable to placebo but average weight loss below some analyst expectations. The readout confirms the drug’s safety profile while leaving questions about competitive positioning versus GLP‑1 and dual-agonist therapies dominating the obesity market. Petrelintide’s mechanism leverages amylin receptor activation to reduce appetite and caloric intake; developers pitched the peptide as a differentiated approach to weight loss. The reported tolerability may support further development, but efficacy comparisons to market leaders could pressure partner Roche on strategic next steps. Industry watchers note the crowded obesity drug landscape and emphasize the need for differentiated efficacy or safety advantages to secure commercial traction. Zealand and Roche will weigh whether to pursue larger trials, combination strategies, or niche positioning.